Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.

Autor: Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité -Universitätsmedizin Berlin, Germany., Giménez-Arnau A; Dermatology Department, Hospital del Mar. IMIM, Universitat Autònoma, Barcelona, Spain., Ensina LF; CPAlpha Clinical Research Center, São Paulo, Brazil.; Hospital Sírio-Libanês, São Paulo, Brazil., Chu CY; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Jaumont X; Novartis Pharma AG, Basel, Switzerland., Tassinari P; Novartis Pharma AG, Basel, Switzerland.
Jazyk: angličtina
Zdroj: The World Allergy Organization journal [World Allergy Organ J] 2020 Sep 12; Vol. 13 (9), pp. 100460. Date of Electronic Publication: 2020 Sep 12 (Print Publication: 2020).
DOI: 10.1016/j.waojou.2020.100460
Abstrakt: Background: A Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient Evaluation (AWARE) is a non-interventional, multicenter study including patients from Europe, Central and Latin America, Asia-Pacific, and the Middle East. AWARE describes real-world evidence for CU, including clinical characteristics, treatment patterns and the impact on quality of life.
Methods: Over the 2-year study, therapy changes, angioedema occurrence, and patient-reported outcomes (PROs) were recorded over 9 visits, including dermatology life quality index (DLQI) and 7-day urticaria activity score (UAS7). Data were stratified into subgroups: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or CSU + CIndU.
Results: Out of 4838 patients analyzed, 9.9% were receiving no treatment for their CU symptoms at baseline, and 20.4% were receiving first-line non-sedating H 1 -antihistamine at approved doses. The predominant baseline therapy was up-dosed non-sedating H 1 -antihistamines (25.5%). By Visit 2, omalizumab was the overall most commonly used therapy (29.6%), increasing to 30.1% by the end of the study. Baseline DLQI scores for patients with CSU, CIndU and CSU + CIndU were 8.3, 7.6 and 9.1, respectively; scores decreased over the study for CSU and CSU + CIndU patients, but fluctuated for CIndU patients. Baseline angioedema occurrence was higher in CSU and CSU + CIndU patients, reported in 45.4% and 45.5% of patients, respectively, compared to 17.0% in CIndU patients. By the final visit, angioedema had decreased to 11.9% and 11.2% for CSU and CSU + CIndU, respectively, and 9.6% for CIndU.
Conclusion: CU patients are undertreated at baseline; after entering the AWARE study, more patients received appropriate treatment. However, over two thirds are not escalated to third-line treatments.
Competing Interests: M. Maurer has received grant/research support and/or honoraria for consulting or lectures from Aralez, Allakos, FAES, Genentech, Merckle Recordati, Moxie, Novartis, Roche, Sanofi, MSD, UCB, Uriach. A. Giménez-Arnau has served as medical advisor for Uriach Pharma, Genentech, Novartis, FAES, GSK, Sanofi, and received research grants supported by Uriach Pharma, Novartis, Grants from Instituto Carlos III- FEDER and has been involved in educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO Pharma, GSK, MSD, Almirall and Sanofi. LF Ensina has received advisory board, speaker and investigator fees from Novartis, and speaker fees from Takeda. C–Y Chu is a clinical trial investigator for Novartis and has received travel support, consulting fees and payment for lectures from Novartis. X. Jaumont and P. Tassinari are employees of Novartis.
(© 2020 The Authors.)
Databáze: MEDLINE
Externí odkaz: